Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD

Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)

Philips and Medtronic partner to upskill 300+ clinicians in structural heart imaging in India

Emcure Pharmaceuticals inaugurates R&D centre in Ahmedabad

The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations

Yatharth Hospital becomes Uttar Pradesh's first JCI-accredited hospital

JCI accreditation is recognized globally

Lupin’s R&D facility in Pune bags LEED Platinum Certification

Reaffirms Lupin’s commitment to sustainable resource management

CDSCO, NRAI meets WHO international standards for vaccine regulations

India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI

Jubilant Ingrevia becomes only Indian company to join WEF’s Global Lighthouse Network

WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse

FDA approves Bristol Myers Squibb’s Cobenfy

A first-in-class muscarinic agonist for the treatment of schizophrenia in adults

Sanofi’s dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype

Indian doctor participates in Jordan’s first robotic radical hysterectomies